Genea Biocells Pty Ltd of Australia used to be a subsidiary of Genea Limited (formerly Sydney IVF Limited), a public, unlisted company that has been operating IVF clinics in Australia since 1985. Genea Biocells Pty Ltd was governed by the same strong ethical principles and corporate governance practices.
Genea Biocells was located in Sydney, Australia and had been supplying commercial stem cell solutions for several years, drawing on an almost 30 year research heritage within Genea. Their team was high class for the times with stem cell research
Genea Biocells used to supply and develop disease-specific pluripotent and differentiated human stem cells for use in drug development and research. The Company’s cellular products were human cells – the most accurate in vitro reflection of clinical conditions at that time, promising more predictive disease models and thereby reducing the need for animal studies. GBC provides the following products for use in drug development and medical research:
- Was the world’s largest private bank of pluripotent human embryonic stem cells. More than 100 cell lines representing almost 30 genetic diseases in a variety of genetic backgrounds. Cell lines include human embryonic stem cells (hESC) and genetically modified cell lines upon specific request.
- Was the world’s only commercially-available, application-ready differentiated disease specific cell types (available from any GBC stem cell line).
- Building on extensive expertise in stem cell differentiation and design of stem cell assays, Genea Biocells offers contract research services to generate customised solutions for drug development using pluripotent or differentiated human cells.
- A unique specialised stem cell medium (Genea M2) – serum-free, fully-defined and applicable for high throughput screening applications.
Human embryonic stem cell lines were available at Genea Biocells and at that time when they were selling them were derived from excess ART embryos and those unsuitable for further clinical use. These embryos were excess to the clinical requirements of Genea patients and have been specifically donated for stem cell derivation. Embryo donation for research purposes is subject to strict ethical and regulatory mechanisms. Consent was voluntary, fully informed and offered to couples as an alternative to discard of excess embryos.
Who Headed Stem Cell Research At Genea Biocells ?
Heather pursued her doctoral studies at Karolinska Institutet in Stockholm, Sweden, and has over a decade of experience researching the development of brain cells from embryonic stem cells, spanning five countries. Presently, she held the position of Senior Scientist at Genea Biocells, Australia. The company focused on disease modeling using human embryonic stem cells derived from preimplantation genetic diagnosis (PGD). Since earning her degree in Molecular Biology in 2001, Heather has actively engaged in science communication, collaborating with EuroStemCell since 2005.
Heather has an extensive body of work in the field of stem cells and regenerative medicine , here is the top list of her collaborations
- A Human Pluripotent Stem Cell Model of Facioscapulohumeral Muscular Dystrophy-Affected Skeletal Muscles.
- Derivation of Trisomy 21 affected human embryonic stem cell line Genea021.
- Derivation of Huntington Disease affected Genea018 human embryonic stem cell line.
- Derivation of NEM2 affected human embryonic stem cell line Genea078.
- Derivation of DM1 affected human embryonic stem cell line Genea067.
- Derivation of FSHD1 affected human embryonic stem cell line Genea050.
- Karolinska Institutet Human Embryonic Stem Cell Bank.
- Managing the potential and pitfalls during clinical translation of emerging stem cell therapies.
What are the usage terms of Genea Biocells?
With a focus on scholarly research, testing, and firsthand experience in stem cells and stem cell research, we fully encourage and support those that wish to use any of the content we put forward. So, if you are wondering how to use the data on Genea Biocells, it is free! Well, as long as you give credit where credit is due.
All the articles are copyrighted and they belong to Genea Biocells. So, in order to use our content, all of the visual material belongs to Genea Biocells and a citation is required before taking the content. We also strongly suggest that you link to the source where you got the information as this ensures Google does not mark your article as plagiarism.
Genea Biocells protects the integrity and anonymity of user data and only collects data information that is opted into via email signups, purchases, and personal contact. We do not share your personal identifiable information with any third party businesses.
What is the Content Integrity of Genea Biocells?
Content Integrity is the process of managing and assuring the integrity and accuracy of information that is made available to the general public. In regards to Genea Biocells, that means that we do not share content unless it has been audited and checked for complete accuracy to the best of our ability in the realm of stem cells and stem cell research.
Starting with a strict editorial process, Genea Biocells publishes content in a way that does not allow for ambiguity or misleading information. Our selection and recommendations use conscious language which is the science of choosing words that only express true intent in the field of stem cell research.
Genea Biocells values the end users’ health above all else and recommends that you consult with your research specialists and scientific advisors before making any major decisions related to stem cells and stem cell research. While we perform our due diligence and make it our mission to protect every user that interacts with our content, science in the realm of stem cells is constantly changing.
How is the Genea Biocells Editorial Process?
The Genea Biocells editorial process is a multitiered approach to ensure absolute integrity and the prioritization of accuracy in stem cell research. Earning and maintaining the trust of our readers is a priority at Genea Biocells. We are always striving to make changes to our content by updating and continual monitoring of the content, regular content audits, and annual brand vetting.
Genea Biocells maintains rigorous standards regarding all content that is published while also making it a priority to use inclusive language in our editorial process. This is to ensure diversity is acknowledged and all populations are represented, especially since having empathy with researchers and readers is critical to our success in the field of stem cell research.
How does Genea Biocells value diversity, equity and inclusion?
Genea Biocells not only uses inclusive language when conveying content to our viewers, but we also include every type of person, from every community, in our stem cell research and studies. From supporting black communities and researchers to respecting the LGBTQ+ community, Genea Biocells is committed to advancing stem cell research for the benefit of everyone.
Scientific Publication Genea Biocells Is Featured in
- A Human Pluripotent Stem Cell Model
- Retrotransposition in human induced pluripotent stem cells